JonesResearch lowered the firm’s price target on Acrivon Therapeutics (ACRV) to $7 from $22 and keeps a Buy rating on the shares. The firm pushed back the launch in endometrial cancer to 2028 from 2027, reduced the technology value to $80M from $175MM and reduced the trading multiple for the shares post the research and development day.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRV:
- Acrivon Therapeutics price target lowered to $10 from $18 at Oppenheimer
- Acrivon Therapeutics reports Q4 EPS (60c), consensus (70c)
- Acrivon Therapeutics Reports 2024 Financial Results and Progress
- Promising Phase 2 Results for ACR-368 in Endometrial Cancer Justify Buy Rating
- Acrivon Therapeutics price target lowered to $19 from $22 at H.C. Wainwright